Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

NCT03735446 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Sponsor Decision

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions

DRUG: Prexasertib
DRUG: Mitoxantrone
DRUG: Etoposide
DRUG: Cytarabine

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]